• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Diamond Equity Research 2020 Virtual Emerging Growth Invitational

    11/24/20 9:30:00 AM ET
    $LTRN
    $VNRX
    $CMTL
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $LTRN alert in real time by email

    NEW YORK, NY / ACCESSWIRE / November 24, 2020 / Diamond Equity Research Emerging Growth Invitational

    2020 Virtual Conference

    • One Day Conference December 1, 2020
    • 20 Minute presenting time slots from 9am to 5pm EST
    • Presentation times and links available distributed for all presenting companies
    • Investors will be provided time after presentation to ask questions to management teams
    • We welcome all institutional and retail investors

    "The Diamond Equity Research Emerging Growth Invitational offers a unique opportunity for investors to evaluate under the radar public companies and ask relevant questions directly to management in a streamlined convenient format." stated Hunter Diamond, CFA the CEO of Diamond Equity Research.

    Investors can register at https://www.diamondequityresearch.com/conferences/.

    Virtual Agenda - Tuesday, December 1, 2020

    8:30-9:00

    Panel: "Evaluating Small Capitalization Investment Opportunities" Speaker: Scott Powell of Skyline Corporate Communications

    9:00-9:20

    Volition Rx (NASDAQ:VNRX)

    9:40-10:00

    Color Star Technology Co., Ltd. (NASDAQ:CSCW)

    10:20-10:40

    Diginex Limited (NASDAQ:EQOS)

    11:00-11:20

    FLYHT Aerospace Solutions Ltd. (OTCQX:FLYLF)

    11:40-12:00

    Genprex Inc. (NASDAQ:GNPX)

    12:20-12:40

    Lantern Pharma Inc. (NASAQ:LTRN)

    1:00-1:20

    Assure Holdings Corp. (OTCQB:ARHH)

    1:40-2:00

    LightPath Technologies, Inc. (NASDAQ:LPTH)

    2:20-2:40

    Midwest Energy Emissions Corp. (OTCQB:MEEC)

    3:00-3:20

    Comtech Telecommunications Corp. (NASDAQ:CMTL)

    3:40-4:00

    Trxade Group, Inc. (NASDAQ:MEDS)

    4:20-4:40

    Tracker Ventures Corp. (OTC PINK:TLOOF)

    About Diamond Equity

    Diamond Equity Research provides in depth research and analysis on global micro capitalization and small capitalization equities. Diamond Equity Research distributes research to top investment platforms and investors globally, allowing companies to reach investors. Diamond Equity Research is a leading provider of institutional quality research, including company sponsored research. Diamond Equity Research holds quarterly investment conferences, allowing management and investors to meaningfully interact.

    Contact

    For additional questions or to connect with companies after the conference, contact the Diamond Equity Research conference team
    [email protected]

    Disclosures: Statements in these presentations may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements". Such statements are based on expectations, estimates and projections at the time the statements are made and involve many risks and uncertainties such as competitive factors, technological development, market demand and a particular company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues, which could cause actual results or events to differ materially from those presently anticipated. The purpose of this conference and recording of event is to extend visibility for these companies and is in no way a recommendation to buy, sell or hold the respective securities. The accuracy or completeness of any material provided is not guaranteed and unless otherwise indicated, is provided by the companies themselves without Diamond Equity Research's oversight and/or endorsement. Diamond Equity Research may have positions in various presenting companies and may change or update its position without notice and without regard to any presented material by company. Conference participants are reminded to do their own due diligence when researching any companies attending the investment conference or prior to making any investment decisions. Investing in micro capitalization and small capitalization securities is highly speculative with many risks, including a complete loss of one's principal. Various companies in this press release have paid to present at our emerging growth conference. Specific payment disclosures can be found on https://www.diamondequityresearch.com/disclosures/.

    SOURCE:  Diamond Equity Research LLC

    Get the next $LTRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LTRN
    $VNRX
    $CMTL
    $GNPX

    CompanyDatePrice TargetRatingAnalyst
    LightPath Technologies Inc.
    $LPTH
    1/29/2026$15.00Buy
    Canaccord Genuity
    LightPath Technologies Inc.
    $LPTH
    4/28/2025$5.50Buy
    Craig Hallum
    VolitionRX Limited
    $VNRX
    4/8/2025$2.50Buy
    H.C. Wainwright
    LightPath Technologies Inc.
    $LPTH
    1/3/2025$3.00 → $5.00Buy
    H.C. Wainwright
    Comtech Telecommunications Corp.
    $CMTL
    6/25/2024$3.50Underperform → Hold
    Jefferies
    Comtech Telecommunications Corp.
    $CMTL
    12/15/2023$18.25Buy
    B. Riley Securities
    Comtech Telecommunications Corp.
    $CMTL
    12/8/2023$10.00 → $7.50Hold → Underperform
    Jefferies
    VolitionRX Limited
    $VNRX
    2/1/2023Buy → Hold
    The Benchmark Company
    More analyst ratings

    $LTRN
    $VNRX
    $CMTL
    $GNPX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Reynolds Cameron John bought $7,000 worth of shares (20,000 units at $0.35), increasing direct ownership by 0.79% to 2,554,847 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    11/17/25 1:12:19 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    President and CEO Reynolds Cameron John bought $56,100 worth of shares (110,000 units at $0.51), increasing direct ownership by 5% to 2,534,847 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    10/15/25 4:05:45 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Innes Guy Archibald bought $49,038 worth of shares (96,153 units at $0.51), increasing direct ownership by 10% to 1,062,967 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    10/15/25 4:05:33 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LTRN
    $VNRX
    $CMTL
    $GNPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut

    CEO Panna Sharma to Lead Live, Unscripted Platform Walkthrough in Two Interactive Sessions on April 30, 2026 — Open to Investors, Researchers, and the Global Biomedical Community Registration Link & Details Can be Accessed Below Lantern Pharma Inc. (NASDAQ:LTRN) ("Lantern" or the "Company"), an AI-driven clinical-stage precision oncology company, today announced the first public demonstration of withZeta.ai, its multi-agentic AI co-scientist platform, to be held on Thursday, April 30, 2026. The event follows the platform's scientific community debut at the American Association for Cancer Research (AACR) Annual Meeting 2026 and its initial unveiling at Nasdaq MarketSite — and marks th

    4/24/26 7:50:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VolitionRx Announces Acceptance of Compliance Plan by NYSE American

    HENDERSON, Nev., April 23, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that on April 22, 2026, the NYSE American LLC (the "NYSE American") accepted the Company's plan of compliance for continued listing on the exchange. As previously reported, on February 6, 2026, the Company received a notice from the NYSE American stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the "Company Guide") requiring a company to have stockholders' equity of at least $2.0 million if it has reported losses fro

    4/23/26 8:12:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting

    AUSTIN, Texas, April 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract has been selected for publication at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 29 – June 2, 2026 in Chicago, Illinois. The abstract details positive clinical data from studies of predictive biomarkers in patients receiving its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of lung cancer.

    4/22/26 7:00:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    $VNRX
    $CMTL
    $GNPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on LightPath with a new price target

    Canaccord Genuity initiated coverage of LightPath with a rating of Buy and set a new price target of $15.00

    1/29/26 7:01:51 AM ET
    $LPTH
    Semiconductors
    Technology

    Craig Hallum initiated coverage on LightPath with a new price target

    Craig Hallum initiated coverage of LightPath with a rating of Buy and set a new price target of $5.50

    4/28/25 8:43:14 AM ET
    $LPTH
    Semiconductors
    Technology

    H.C. Wainwright initiated coverage on VolitionRx with a new price target

    H.C. Wainwright initiated coverage of VolitionRx with a rating of Buy and set a new price target of $2.50

    4/8/25 8:02:28 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LTRN
    $VNRX
    $CMTL
    $GNPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Longnecker Brent M

    4 - Genprex, Inc. (0001595248) (Issuer)

    4/15/26 6:50:54 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Rubin Shmuel

    4 - LIGHTPATH TECHNOLOGIES INC (0000889971) (Issuer)

    3/30/26 9:22:42 AM ET
    $LPTH
    Semiconductors
    Technology

    SEC Form 4 filed by Crawford Bruce T

    4 - COMTECH TELECOMMUNICATIONS CORP /DE/ (0000023197) (Issuer)

    3/26/26 4:59:58 PM ET
    $CMTL
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $LTRN
    $VNRX
    $CMTL
    $GNPX
    SEC Filings

    View All

    VolitionRX Limited filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

    8-K - VOLITIONRX LTD (0000093314) (Filer)

    4/23/26 8:45:52 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Genprex Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Genprex, Inc. (0001595248) (Filer)

    4/21/26 7:02:55 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VolitionRX Limited filed SEC Form 8-K: Other Events, Submission of Matters to a Vote of Security Holders

    8-K - VOLITIONRX LTD (0000093314) (Filer)

    4/17/26 5:00:24 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LTRN
    $VNRX
    $CMTL
    $GNPX
    Leadership Updates

    Live Leadership Updates

    View All

    LightPath Appoints Two Senior Sales Executives to Drive Defense and Commercial Growth

    Seasoned Defense and Aerospace Executives to Drive Revenue Growth and Expand Market Reach Across LightPath's Defense and Commercial PlatformsORLANDO, Fla., April 8, 2026 /PRNewswire/ -- LightPath Technologies, Inc. (NASDAQ:LPTH) ("LightPath," the "Company," "we," or "our"), a leading provider of next-generation optics and imaging systems for both defense and commercial applications, today announced the appointments of Doug Schoen as Senior Vice President of Global Sales and Ryan Workman as Vice President, Business Development & Product Management, effective April 6, 2026. Both executives bring extensive defense industry leadership experience and will play key roles in accelerating the Compan

    4/8/26 8:31:00 AM ET
    $LPTH
    Semiconductors
    Technology

    Volition Announces the Appointment of New Distributor for Nu.Q® Discover

    HENDERSON, Nev., Feb. 10, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor of its Nu.Q® Discover assays in Japan. Dr Jasmine Kway, Chief Executive Officer, Singapore Volition commented: "We are delighted to be working with MBL, a leading provider of clinical research tools in Japan, with a particular focus and track record in autoimmune diseases. "Through our Nu.Q® Discover pillar, we are now serving close to 100 clients worldwide, including many top pharma and diagnostic companies, accelerating disease research and drug developme

    2/10/26 8:07:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    LightPath Technologies Acquires Amorphous Materials, Inc.

    Strategic Purchase to Add Proprietary Large Diameter Glass Melting Technology of Chalcogenide Glass ORLANDO, Fla., Jan. 20, 2026 /PRNewswire/ -- LightPath Technologies, Inc. (NASDAQ:LPTH) ("LightPath," the "Company," "we," or "our"), a leading provider of next-generation optics and imaging systems for both defense and commercial applications, today announced it has acquired the assets of Amorphous Materials, Inc., ("AMI") an industrial manufacturer with complementary Chalcogenide glass melting technologies, in particular for large diameter optics, purchased for aggregate consideration of $7.0 million in cash, with the potential for up to $3 million of additional technical milestone-based equ

    1/20/26 4:59:00 PM ET
    $LPTH
    Semiconductors
    Technology

    $LTRN
    $VNRX
    $CMTL
    $GNPX
    Financials

    Live finance-specific insights

    View All

    VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

    Conference call to discuss financial and operational results scheduled forWednesday, April 1 at 8:30 a.m. U.S. Eastern TimeHENDERSON, Nev., March 31, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the full fiscal year 2025.  Volition management will host a conference call tomorrow, April 1 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below. Cameron Reynolds, President and Group Chief Executive Officer, said:"We set out over fifteen years ago to help save lives and improve outcomes for millions of

    3/31/26 4:05:00 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

    Year of Clinical Validation and Strategic Expansion Across Pipeline, AI Platform Advances Towards Commercialization, and Global Trial Milestones LP-300 Phase 2 HARMONIC™ Trial Progress: Continued enrollment and patient follow-up across the United States, Japan, and Taiwan. Completion of targeted enrollment in Japan across five clinical sites including the National Cancer Center Tokyo. Preliminary data presented at the 66th Annual Meeting of the Japan Lung Cancer Society. Type C meeting package submitted to FDA in March 2026, with meeting scheduled for mid-May 2026 seeking feedback on proposed protocol amendments including focusing enrollment on EGFR exon 21 L858R patients and updating th

    3/30/26 4:05:00 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update

    Conference call to take place on Wednesday, April 1 at 8:30 a.m. U.S Eastern TimeHENDERSON, Nev., March 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Wednesday, April 1 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the full fiscal year 2025 and to provide a business update. Details of this event can be found below. Event: VolitionRx Limited Full Fiscal Year 2025 Earnings and Business Update Conference CallDate:  Wednesday, April 1, 2026Time:  8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European TimeU.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (t

    3/25/26 4:12:00 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LTRN
    $VNRX
    $CMTL
    $GNPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by LightPath Technologies Inc.

    SC 13G/A - LIGHTPATH TECHNOLOGIES INC (0000889971) (Subject)

    12/13/24 3:18:07 PM ET
    $LPTH
    Semiconductors
    Technology

    Amendment: SEC Form SC 13D/A filed by Comtech Telecommunications Corp.

    SC 13D/A - COMTECH TELECOMMUNICATIONS CORP /DE/ (0000023197) (Subject)

    11/18/24 5:30:12 PM ET
    $CMTL
    Radio And Television Broadcasting And Communications Equipment
    Technology

    SEC Form SC 13G filed by VolitionRX Limited

    SC 13G - VOLITIONRX LTD (0000093314) (Subject)

    11/14/24 4:05:14 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care